Eli Lilly and Company (NYSE:LLY) Stake Increased by Glass Wealth Management Co LLC

Glass Wealth Management Co LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 41.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 2,309 shares of the company’s stock after buying an additional 680 shares during the period. Glass Wealth Management Co LLC’s holdings in Eli Lilly and Company were worth $2,046,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. PAX Financial Group LLC lifted its holdings in Eli Lilly and Company by 3.4% during the 1st quarter. PAX Financial Group LLC now owns 458 shares of the company’s stock worth $356,000 after buying an additional 15 shares during the last quarter. Point Break Capital Management LLC lifted its stake in Eli Lilly and Company by 75.9% during the first quarter. Point Break Capital Management LLC now owns 2,401 shares of the company’s stock worth $1,868,000 after purchasing an additional 1,036 shares during the last quarter. Hilltop Partners LLC boosted its holdings in Eli Lilly and Company by 7.9% in the first quarter. Hilltop Partners LLC now owns 975 shares of the company’s stock worth $758,000 after purchasing an additional 71 shares during the period. Capitolis Liquid Global Markets LLC bought a new stake in Eli Lilly and Company during the first quarter valued at $86,665,000. Finally, Atlanta Consulting Group Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter valued at $365,000. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $746.20 on Monday. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The firm has a market cap of $708.38 billion, a P/E ratio of 80.67, a PEG ratio of 2.82 and a beta of 0.43. The stock has a fifty day moving average price of $882.65 and a two-hundred day moving average price of $871.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period in the previous year, the firm earned $0.10 earnings per share. Eli Lilly and Company’s revenue was up 20.4% on a year-over-year basis. Research analysts forecast that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research reports. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. BMO Capital Markets upped their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Barclays cut their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Citigroup upped their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Finally, Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday. They issued an “outperform” rating and a $1,000.00 target price on the stock. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.